Growth Factors Emerge as Non-Invasive Anti-Aging Contender

Growth factor serums are now widely available at retailers like Sephora and Ulta, promising to smooth wrinkles and improve skin texture without needles or downtime. This shift from medical-grade exclusivity to mainstream shelves is driven by ingredient-savvy shoppers, according to Anna Mayo, Vice President for NielsenIQ's Beauty Vertical.

Younger consumers are particularly invested. Mayo notes that millennials and younger demographics report greater concern about aging and a willingness to invest in prevention. This aligns with broader sentiment, as 60% of Americans express concern about growing old and already purchase specialized products for health and appearance.

How Growth Factors Work

Cosmetic chemist Gloria Lu explains that growth factors are signaling proteins that instruct skin cells, promoting functions like cell proliferation, healing, and collagen production. Their discovery dates to 1962, when biochemist Stanley Cohen first identified epidermal growth factors (EGFs), a breakthrough that later earned a Nobel Prize.

However, a key challenge is skin penetration. Dr. Lauren Moy, a double board-certified dermatologist, states that growth factors are large proteins, and intact skin effectively blocks them. Formulations may use liposomes, exosomes, or encapsulation technologies to improve delivery, especially after procedures that temporarily impair the skin barrier.

When effective penetration is achieved, brands claim significant results. Glo Skin’s EGF neck cream promises visible improvements in 30 days, while SkinMedica’s TNS® Advanced+ Serum has smoother wrinkles in as early as two weeks. Despite a perception of novelty, brands like SkinMedica have over 25 years of research, having launched one of the first growth factor serums in 2001.

Sourcing and Ethical Considerations

Growth factors in skincare are sourced from human, synthetic, or other biological origins, leading to varied formulations and ethical debates.

Dr. Ben Johnson, founder of Osmosis, clarifies that human-derived skincare does not contain actual human tissue. The process involves isolating fibroblasts from donated tissue, growing them in a lab, and using the released growth factors. Ethical concerns arise regarding donor consent. Ryan Pferdehirt, Vice President of Ethics Services at the Center for Practical Bioethics, doubts donors are informed their tissue might be used in cosmetics. He states, “I highly doubt that individuals are told about the skincare or the cosmetic nature of where these donations may be going towards.”

Pferdehirt argues that if sourcing is ethical, the confidence benefits from such cosmetics can outweigh harms. However, he emphasizes that non-consensual procurement, such as through human trafficking, would reverse that balance. He urges consumers to demand transparency from companies, noting that most remain opaque about their sourcing processes. Regulatory differences exist, with the European Union prohibiting human-derived cells in cosmetics while the United States allows them.

Advancements in biotechnology offer alternatives. Dr. Jason B. Diamond, a plastic surgeon, highlights that synthetic growth factors provide greater consistency, scalability, and purity control, reducing ethical concerns related to biologic variability. His brand uses bio-identical growth factors. Similarly, Glo Skin Beauty employs a vegan epidermal growth factor with the same amino acid sequence as human versions but produced without human or animal sources.

As the market grows, consumer demand for clarity may push brands toward greater transparency in their ingredient sourcing and ethical standards.